Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
Research using PPMI data and imaging will be presented at the American Academy of Neurology (AAN) 2014 Annual Meeting happening April 26 to May 3 in Philadelphia, PA.
An inventory of the available imaging from PPMI is now viewable on the Access Data & Specimens page on www.ppmi-info.org. The inventory table is updated in real-time, providing researchers with a summary of what images are available before they submit a request for access.
Using a single application, qualified researchers may request access to clinical data and biospecimens from a collection of studies exploring promising areas in Parkinson’s research, including PPMI. The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is also offering funding for use and analysis of the available information and materials. Applicants may request up to […]
In late February, a press release officially announced the launch of PPMI’s new study arm to examine the role of genetic mutations in Parkinson’s disease. Leveraging the robust infrastructure already established in PPMI, the study expanded to enroll individuals with mutations of the LRRK2 and SNCA genes. The expansion was reported globally by Jewish publications, […]
A letter from the PPMI Steering Committee regarding the status of CSF Data.